SUNNYVALE, Calif., Nov. 11 /PRNewswire/ -- Biocircuits Corporation
(Nasdaq: BIOC) announced today that transfer of sales and marketing
responsibilities for the IOS(R) system will occur on November 17th.
Biocircuits previously announced the signing of an agreement with Becton
Dickinson whereby Becton Dickinson acquired the exclusive worldwide sales and
marketing rights for the I0S system and all present and future cartridges.
Training of the Becton Dickinson US Point Of Care sales force will occur at
the Becton Dickinson national sales meeting on November 15th.
    Under the terms of the agreement, Becton Dickinson also acquired the right
to manufacture the IOS system instrument commencing January 1, 1998.
Biocircuits will continue to manufacture all test cartridges and to develop
new cartridges, including tests for Digoxin, Free T4 and PSA.  Decisions for
the selection of the next tests for development will be shared by both
companies.
    The IOS system is the first easy to use and economical system for
performing immunoassays in locations such as the physician's office.  Although
approximately 36,000 such sites currently have the requisite moderately
complex license for performing such tests, most send the testing out to large
laboratories since an appropriate system has not been available to do the
testing at the site.  Becton Dickinson currently sells the QBC(R) hematology
system and the Affirm VP(R) system to these moderately complex licensed
facilities.
    Actual results may differ from the above forward looking statement due to
a number of important factors, and will be dependent upon Becton Dickinson
successfully manufacturing the IOS instrument and marketing the existing and
proposed products, as well as the timely development and regulatory approval
of additional products.  Additional risk factors are more fully discussed in
the Company's most recent reports on Forms 10-K and 10-Q and the Company's
resale Registration Statement No. 333-26079.

Link to this page: